nodes	percent_of_prediction	percent_of_DWPC	metapath
Esmolol—Pleuritic pain—Bleomycin—melanoma	0.0407	0.0477	CcSEcCtD
Esmolol—Tonic-clonic seizures—Carmustine—melanoma	0.0265	0.031	CcSEcCtD
Esmolol—Skin necrosis—Carmustine—melanoma	0.0204	0.0239	CcSEcCtD
Esmolol—Rales—Bleomycin—melanoma	0.0199	0.0233	CcSEcCtD
Esmolol—Induration—Bleomycin—melanoma	0.0183	0.0214	CcSEcCtD
Esmolol—Angina unstable—Docetaxel—melanoma	0.0181	0.0213	CcSEcCtD
Esmolol—Rigors—Vemurafenib—melanoma	0.0165	0.0194	CcSEcCtD
Esmolol—Grand mal convulsion—Carmustine—melanoma	0.015	0.0176	CcSEcCtD
Esmolol—Extravasation—Bleomycin—melanoma	0.00936	0.011	CcSEcCtD
Esmolol—Extravasation—Dactinomycin—melanoma	0.00873	0.0102	CcSEcCtD
Esmolol—Rigors—Temozolomide—melanoma	0.00844	0.00989	CcSEcCtD
Esmolol—Speech disorder—Carmustine—melanoma	0.00829	0.00972	CcSEcCtD
Esmolol—Extravasation—Carmustine—melanoma	0.00817	0.00958	CcSEcCtD
Esmolol—Speech disorder—Temozolomide—melanoma	0.00801	0.00939	CcSEcCtD
Esmolol—Wheezing—Bleomycin—melanoma	0.00793	0.0093	CcSEcCtD
Esmolol—Skin exfoliation—Bleomycin—melanoma	0.00779	0.00914	CcSEcCtD
Esmolol—Thinking abnormal—Carmustine—melanoma	0.00778	0.00913	CcSEcCtD
Esmolol—Neuropathy peripheral—Vemurafenib—melanoma	0.00739	0.00867	CcSEcCtD
Esmolol—Respiratory failure—Temozolomide—melanoma	0.00701	0.00823	CcSEcCtD
Esmolol—Skin exfoliation—Carmustine—melanoma	0.0068	0.00798	CcSEcCtD
Esmolol—Neuropathy—Carmustine—melanoma	0.00669	0.00785	CcSEcCtD
Esmolol—Skin exfoliation—Temozolomide—melanoma	0.00657	0.00771	CcSEcCtD
Esmolol—Neuropathy—Temozolomide—melanoma	0.00647	0.00758	CcSEcCtD
Esmolol—Cardiac disorder—Vemurafenib—melanoma	0.00628	0.00737	CcSEcCtD
Esmolol—Abnormal vision—Carmustine—melanoma	0.00622	0.00729	CcSEcCtD
Esmolol—Mental disability—Carmustine—melanoma	0.00618	0.00725	CcSEcCtD
Esmolol—Angiopathy—Vemurafenib—melanoma	0.00614	0.0072	CcSEcCtD
Esmolol—Chills—Vemurafenib—melanoma	0.00607	0.00712	CcSEcCtD
Esmolol—Abnormal vision—Temozolomide—melanoma	0.00601	0.00704	CcSEcCtD
Esmolol—Pleural effusion—Docetaxel—melanoma	0.00598	0.00701	CcSEcCtD
Esmolol—Mental disability—Temozolomide—melanoma	0.00598	0.00701	CcSEcCtD
Esmolol—Thrombophlebitis—Carmustine—melanoma	0.00598	0.00701	CcSEcCtD
Esmolol—Erythema—Vemurafenib—melanoma	0.00589	0.00691	CcSEcCtD
Esmolol—Thrombophlebitis—Temozolomide—melanoma	0.00577	0.00677	CcSEcCtD
Esmolol—Dysgeusia—Vemurafenib—melanoma	0.00577	0.00677	CcSEcCtD
Esmolol—Myocardial ischaemia—Docetaxel—melanoma	0.0057	0.00668	CcSEcCtD
Esmolol—Rigors—Docetaxel—melanoma	0.00561	0.00658	CcSEcCtD
Esmolol—Nasal congestion—Temozolomide—melanoma	0.00549	0.00644	CcSEcCtD
Esmolol—Extravasation—Docetaxel—melanoma	0.00525	0.00616	CcSEcCtD
Esmolol—Bronchospasm—Bleomycin—melanoma	0.00504	0.00591	CcSEcCtD
Esmolol—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00498	0.00584	CcSEcCtD
Esmolol—Oliguria—Docetaxel—melanoma	0.00497	0.00583	CcSEcCtD
Esmolol—Inflammation—Docetaxel—melanoma	0.00472	0.00554	CcSEcCtD
Esmolol—Nervous system disorder—Vemurafenib—melanoma	0.00471	0.00553	CcSEcCtD
Esmolol—Skin disorder—Vemurafenib—melanoma	0.00467	0.00548	CcSEcCtD
Esmolol—Respiratory failure—Docetaxel—melanoma	0.00466	0.00547	CcSEcCtD
Esmolol—Acute coronary syndrome—Bleomycin—melanoma	0.0045	0.00528	CcSEcCtD
Esmolol—Hypotension—Vemurafenib—melanoma	0.00449	0.00527	CcSEcCtD
Esmolol—Myocardial infarction—Bleomycin—melanoma	0.00448	0.00525	CcSEcCtD
Esmolol—Ibuprofen—BCL2—melanoma	0.00439	0.194	CrCbGaD
Esmolol—Skin exfoliation—Docetaxel—melanoma	0.00437	0.00513	CcSEcCtD
Esmolol—Neuropathy—Docetaxel—melanoma	0.0043	0.00504	CcSEcCtD
Esmolol—Sweating increased—Temozolomide—melanoma	0.00421	0.00494	CcSEcCtD
Esmolol—Decreased appetite—Vemurafenib—melanoma	0.00418	0.0049	CcSEcCtD
Esmolol—Gastrointestinal disorder—Vemurafenib—melanoma	0.00415	0.00487	CcSEcCtD
Esmolol—Fatigue—Vemurafenib—melanoma	0.00414	0.00486	CcSEcCtD
Esmolol—Constipation—Vemurafenib—melanoma	0.00411	0.00482	CcSEcCtD
Esmolol—Lightheadedness—Docetaxel—melanoma	0.0041	0.00481	CcSEcCtD
Esmolol—Pulmonary oedema—Docetaxel—melanoma	0.00408	0.00478	CcSEcCtD
Esmolol—Dysuria—Temozolomide—melanoma	0.00404	0.00474	CcSEcCtD
Esmolol—Neuropathy peripheral—Carmustine—melanoma	0.00391	0.00458	CcSEcCtD
Esmolol—Thrombophlebitis—Docetaxel—melanoma	0.00384	0.0045	CcSEcCtD
Esmolol—Flushing—Bleomycin—melanoma	0.0038	0.00446	CcSEcCtD
Esmolol—Body temperature increased—Vemurafenib—melanoma	0.0038	0.00446	CcSEcCtD
Esmolol—Pharyngitis—Dactinomycin—melanoma	0.00379	0.00445	CcSEcCtD
Esmolol—Neuropathy peripheral—Temozolomide—melanoma	0.00378	0.00443	CcSEcCtD
Esmolol—Chills—Bleomycin—melanoma	0.00368	0.00431	CcSEcCtD
Esmolol—Cardiac failure congestive—Docetaxel—melanoma	0.00367	0.0043	CcSEcCtD
Esmolol—Erythema—Bleomycin—melanoma	0.00357	0.00419	CcSEcCtD
Esmolol—Flushing—Dactinomycin—melanoma	0.00355	0.00416	CcSEcCtD
Esmolol—Ibuprofen—CXCL8—melanoma	0.00352	0.156	CrCbGaD
Esmolol—Dermatitis bullous—Docetaxel—melanoma	0.00348	0.00408	CcSEcCtD
Esmolol—Asthenia—Vemurafenib—melanoma	0.00345	0.00405	CcSEcCtD
Esmolol—Visual impairment—Carmustine—melanoma	0.00345	0.00405	CcSEcCtD
Esmolol—Pharyngitis—Temozolomide—melanoma	0.00343	0.00403	CcSEcCtD
Esmolol—Chills—Dactinomycin—melanoma	0.00343	0.00402	CcSEcCtD
Esmolol—Urinary tract disorder—Temozolomide—melanoma	0.00342	0.00401	CcSEcCtD
Esmolol—Cardiac failure—Docetaxel—melanoma	0.00341	0.004	CcSEcCtD
Esmolol—Pruritus—Vemurafenib—melanoma	0.0034	0.00399	CcSEcCtD
Esmolol—Urethral disorder—Temozolomide—melanoma	0.00339	0.00398	CcSEcCtD
Esmolol—Visual impairment—Temozolomide—melanoma	0.00333	0.00391	CcSEcCtD
Esmolol—Erythema—Dactinomycin—melanoma	0.00333	0.0039	CcSEcCtD
Esmolol—Flushing—Carmustine—melanoma	0.00332	0.0039	CcSEcCtD
Esmolol—Cardiac disorder—Temozolomide—melanoma	0.00321	0.00376	CcSEcCtD
Esmolol—Flushing—Temozolomide—melanoma	0.00321	0.00376	CcSEcCtD
Esmolol—Dizziness—Vemurafenib—melanoma	0.00318	0.00373	CcSEcCtD
Esmolol—Angiopathy—Temozolomide—melanoma	0.00314	0.00368	CcSEcCtD
Esmolol—Mental disorder—Carmustine—melanoma	0.00314	0.00368	CcSEcCtD
Esmolol—Erythema—Carmustine—melanoma	0.00312	0.00365	CcSEcCtD
Esmolol—Chills—Temozolomide—melanoma	0.0031	0.00364	CcSEcCtD
Esmolol—Vomiting—Vemurafenib—melanoma	0.00306	0.00359	CcSEcCtD
Esmolol—Chest pain—Bleomycin—melanoma	0.00304	0.00356	CcSEcCtD
Esmolol—Mental disorder—Temozolomide—melanoma	0.00303	0.00355	CcSEcCtD
Esmolol—Headache—Vemurafenib—melanoma	0.00301	0.00353	CcSEcCtD
Esmolol—Erythema—Temozolomide—melanoma	0.00301	0.00353	CcSEcCtD
Esmolol—Nasopharyngitis—Docetaxel—melanoma	0.00297	0.00349	CcSEcCtD
Esmolol—Dysgeusia—Temozolomide—melanoma	0.00295	0.00346	CcSEcCtD
Esmolol—Confusional state—Bleomycin—melanoma	0.00294	0.00344	CcSEcCtD
Esmolol—Oedema—Bleomycin—melanoma	0.00291	0.00342	CcSEcCtD
Esmolol—Agitation—Carmustine—melanoma	0.00286	0.00336	CcSEcCtD
Esmolol—Nausea—Vemurafenib—melanoma	0.00286	0.00335	CcSEcCtD
Esmolol—Bronchospasm—Docetaxel—melanoma	0.00283	0.00331	CcSEcCtD
Esmolol—Angina pectoris—Docetaxel—melanoma	0.0028	0.00328	CcSEcCtD
Esmolol—Anorexia—Bleomycin—melanoma	0.00278	0.00326	CcSEcCtD
Esmolol—Agitation—Temozolomide—melanoma	0.00277	0.00324	CcSEcCtD
Esmolol—Angioedema—Temozolomide—melanoma	0.00275	0.00323	CcSEcCtD
Esmolol—Hypotension—Bleomycin—melanoma	0.00272	0.00319	CcSEcCtD
Esmolol—Oedema—Dactinomycin—melanoma	0.00272	0.00319	CcSEcCtD
Esmolol—Convulsion—Carmustine—melanoma	0.0027	0.00317	CcSEcCtD
Esmolol—Chest pain—Carmustine—melanoma	0.00265	0.00311	CcSEcCtD
Esmolol—Anxiety—Carmustine—melanoma	0.00264	0.0031	CcSEcCtD
Esmolol—Paraesthesia—Bleomycin—melanoma	0.00262	0.00307	CcSEcCtD
Esmolol—Convulsion—Temozolomide—melanoma	0.00261	0.00306	CcSEcCtD
Esmolol—Dyspnoea—Bleomycin—melanoma	0.0026	0.00305	CcSEcCtD
Esmolol—Anorexia—Dactinomycin—melanoma	0.00259	0.00304	CcSEcCtD
Esmolol—Confusional state—Carmustine—melanoma	0.00256	0.00301	CcSEcCtD
Esmolol—Anxiety—Temozolomide—melanoma	0.00255	0.003	CcSEcCtD
Esmolol—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00255	0.00299	CcSEcCtD
Esmolol—Oedema—Carmustine—melanoma	0.00254	0.00298	CcSEcCtD
Esmolol—Decreased appetite—Bleomycin—melanoma	0.00253	0.00297	CcSEcCtD
Esmolol—Acute coronary syndrome—Docetaxel—melanoma	0.00253	0.00296	CcSEcCtD
Esmolol—Neuropathy peripheral—Docetaxel—melanoma	0.00251	0.00295	CcSEcCtD
Esmolol—Myocardial infarction—Docetaxel—melanoma	0.00251	0.00295	CcSEcCtD
Esmolol—Dry mouth—Temozolomide—melanoma	0.00251	0.00294	CcSEcCtD
Esmolol—Pain—Bleomycin—melanoma	0.00249	0.00292	CcSEcCtD
Esmolol—Confusional state—Temozolomide—melanoma	0.00248	0.00291	CcSEcCtD
Esmolol—Oedema—Temozolomide—melanoma	0.00246	0.00288	CcSEcCtD
Esmolol—Ibuprofen—PPARG—melanoma	0.00243	0.107	CrCbGaD
Esmolol—Anorexia—Carmustine—melanoma	0.00242	0.00284	CcSEcCtD
Esmolol—Nervous system disorder—Temozolomide—melanoma	0.00241	0.00283	CcSEcCtD
Esmolol—Feeling abnormal—Bleomycin—melanoma	0.0024	0.00282	CcSEcCtD
Esmolol—Skin disorder—Temozolomide—melanoma	0.00239	0.0028	CcSEcCtD
Esmolol—Hypotension—Carmustine—melanoma	0.00238	0.00279	CcSEcCtD
Esmolol—Hyperhidrosis—Temozolomide—melanoma	0.00238	0.00279	CcSEcCtD
Esmolol—Decreased appetite—Dactinomycin—melanoma	0.00236	0.00277	CcSEcCtD
Esmolol—Fatigue—Dactinomycin—melanoma	0.00234	0.00275	CcSEcCtD
Esmolol—Anorexia—Temozolomide—melanoma	0.00234	0.00275	CcSEcCtD
Esmolol—Pain—Dactinomycin—melanoma	0.00232	0.00272	CcSEcCtD
Esmolol—Urticaria—Bleomycin—melanoma	0.00231	0.00271	CcSEcCtD
Esmolol—Rhinitis—Docetaxel—melanoma	0.00231	0.0027	CcSEcCtD
Esmolol—Chlorphenesin—PTGS2—melanoma	0.0023	0.102	CrCbGaD
Esmolol—Body temperature increased—Bleomycin—melanoma	0.0023	0.0027	CcSEcCtD
Esmolol—Paraesthesia—Carmustine—melanoma	0.00228	0.00268	CcSEcCtD
Esmolol—Pharyngitis—Docetaxel—melanoma	0.00228	0.00268	CcSEcCtD
Esmolol—Urinary tract disorder—Docetaxel—melanoma	0.00227	0.00266	CcSEcCtD
Esmolol—Dyspnoea—Carmustine—melanoma	0.00227	0.00266	CcSEcCtD
Esmolol—Somnolence—Carmustine—melanoma	0.00226	0.00265	CcSEcCtD
Esmolol—Urethral disorder—Docetaxel—melanoma	0.00225	0.00264	CcSEcCtD
Esmolol—Feeling abnormal—Dactinomycin—melanoma	0.00224	0.00263	CcSEcCtD
Esmolol—Visual impairment—Docetaxel—melanoma	0.00222	0.0026	CcSEcCtD
Esmolol—Decreased appetite—Carmustine—melanoma	0.00221	0.00259	CcSEcCtD
Esmolol—Paraesthesia—Temozolomide—melanoma	0.00221	0.00259	CcSEcCtD
Esmolol—Gastrointestinal disorder—Carmustine—melanoma	0.0022	0.00257	CcSEcCtD
Esmolol—Dyspnoea—Temozolomide—melanoma	0.00219	0.00257	CcSEcCtD
Esmolol—Somnolence—Temozolomide—melanoma	0.00218	0.00256	CcSEcCtD
Esmolol—Pain—Carmustine—melanoma	0.00217	0.00255	CcSEcCtD
Esmolol—Constipation—Carmustine—melanoma	0.00217	0.00255	CcSEcCtD
Esmolol—Dyspepsia—Temozolomide—melanoma	0.00216	0.00254	CcSEcCtD
Esmolol—Body temperature increased—Dactinomycin—melanoma	0.00215	0.00252	CcSEcCtD
Esmolol—Decreased appetite—Temozolomide—melanoma	0.00214	0.00251	CcSEcCtD
Esmolol—Flushing—Docetaxel—melanoma	0.00213	0.0025	CcSEcCtD
Esmolol—Cardiac disorder—Docetaxel—melanoma	0.00213	0.0025	CcSEcCtD
Esmolol—Gastrointestinal disorder—Temozolomide—melanoma	0.00212	0.00249	CcSEcCtD
Esmolol—Fatigue—Temozolomide—melanoma	0.00212	0.00248	CcSEcCtD
Esmolol—Constipation—Temozolomide—melanoma	0.0021	0.00246	CcSEcCtD
Esmolol—Pain—Temozolomide—melanoma	0.0021	0.00246	CcSEcCtD
Esmolol—Feeling abnormal—Carmustine—melanoma	0.0021	0.00246	CcSEcCtD
Esmolol—Asthenia—Bleomycin—melanoma	0.00209	0.00245	CcSEcCtD
Esmolol—Angiopathy—Docetaxel—melanoma	0.00209	0.00245	CcSEcCtD
Esmolol—Chills—Docetaxel—melanoma	0.00206	0.00242	CcSEcCtD
Esmolol—Pruritus—Bleomycin—melanoma	0.00206	0.00242	CcSEcCtD
Esmolol—Feeling abnormal—Temozolomide—melanoma	0.00202	0.00237	CcSEcCtD
Esmolol—Mental disorder—Docetaxel—melanoma	0.00201	0.00236	CcSEcCtD
Esmolol—Body temperature increased—Carmustine—melanoma	0.00201	0.00236	CcSEcCtD
Esmolol—Erythema—Docetaxel—melanoma	0.002	0.00235	CcSEcCtD
Esmolol—Dysgeusia—Docetaxel—melanoma	0.00196	0.0023	CcSEcCtD
Esmolol—Atenolol—ABCB1—melanoma	0.00196	0.0864	CrCbGaD
Esmolol—Urticaria—Temozolomide—melanoma	0.00195	0.00229	CcSEcCtD
Esmolol—Asthenia—Dactinomycin—melanoma	0.00195	0.00229	CcSEcCtD
Esmolol—Body temperature increased—Temozolomide—melanoma	0.00194	0.00228	CcSEcCtD
Esmolol—Vomiting—Bleomycin—melanoma	0.00185	0.00217	CcSEcCtD
Esmolol—Asthenia—Carmustine—melanoma	0.00182	0.00214	CcSEcCtD
Esmolol—Acebutolol—ABCB1—melanoma	0.00181	0.0798	CrCbGaD
Esmolol—Syncope—Docetaxel—melanoma	0.0018	0.00211	CcSEcCtD
Esmolol—Asthenia—Temozolomide—melanoma	0.00176	0.00207	CcSEcCtD
Esmolol—Loss of consciousness—Docetaxel—melanoma	0.00176	0.00206	CcSEcCtD
Esmolol—Pruritus—Temozolomide—melanoma	0.00174	0.00204	CcSEcCtD
Esmolol—Convulsion—Docetaxel—melanoma	0.00173	0.00203	CcSEcCtD
Esmolol—Nausea—Bleomycin—melanoma	0.00173	0.00203	CcSEcCtD
Esmolol—Vomiting—Dactinomycin—melanoma	0.00173	0.00203	CcSEcCtD
Esmolol—Chest pain—Docetaxel—melanoma	0.0017	0.002	CcSEcCtD
Esmolol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00169	0.00199	CcSEcCtD
Esmolol—Dizziness—Carmustine—melanoma	0.00168	0.00197	CcSEcCtD
Esmolol—Dry mouth—Docetaxel—melanoma	0.00167	0.00196	CcSEcCtD
Esmolol—Confusional state—Docetaxel—melanoma	0.00165	0.00193	CcSEcCtD
Esmolol—Oedema—Docetaxel—melanoma	0.00163	0.00192	CcSEcCtD
Esmolol—Dizziness—Temozolomide—melanoma	0.00162	0.00191	CcSEcCtD
Esmolol—Vomiting—Carmustine—melanoma	0.00162	0.0019	CcSEcCtD
Esmolol—Nausea—Dactinomycin—melanoma	0.00161	0.00189	CcSEcCtD
Esmolol—Shock—Docetaxel—melanoma	0.00161	0.00189	CcSEcCtD
Esmolol—Nervous system disorder—Docetaxel—melanoma	0.0016	0.00188	CcSEcCtD
Esmolol—Headache—Carmustine—melanoma	0.00159	0.00187	CcSEcCtD
Esmolol—Skin disorder—Docetaxel—melanoma	0.00159	0.00186	CcSEcCtD
Esmolol—Vomiting—Temozolomide—melanoma	0.00156	0.00183	CcSEcCtD
Esmolol—Anorexia—Docetaxel—melanoma	0.00156	0.00183	CcSEcCtD
Esmolol—Headache—Temozolomide—melanoma	0.00154	0.00181	CcSEcCtD
Esmolol—Hypotension—Docetaxel—melanoma	0.00153	0.00179	CcSEcCtD
Esmolol—Metoprolol—ABCB1—melanoma	0.00153	0.0673	CrCbGaD
Esmolol—Nausea—Carmustine—melanoma	0.00151	0.00177	CcSEcCtD
Esmolol—Paraesthesia—Docetaxel—melanoma	0.00147	0.00172	CcSEcCtD
Esmolol—Nausea—Temozolomide—melanoma	0.00146	0.00171	CcSEcCtD
Esmolol—Dyspnoea—Docetaxel—melanoma	0.00146	0.00171	CcSEcCtD
Esmolol—Somnolence—Docetaxel—melanoma	0.00145	0.0017	CcSEcCtD
Esmolol—Dyspepsia—Docetaxel—melanoma	0.00144	0.00169	CcSEcCtD
Esmolol—Decreased appetite—Docetaxel—melanoma	0.00142	0.00167	CcSEcCtD
Esmolol—Gastrointestinal disorder—Docetaxel—melanoma	0.00141	0.00165	CcSEcCtD
Esmolol—Fatigue—Docetaxel—melanoma	0.00141	0.00165	CcSEcCtD
Esmolol—Pain—Docetaxel—melanoma	0.0014	0.00164	CcSEcCtD
Esmolol—Constipation—Docetaxel—melanoma	0.0014	0.00164	CcSEcCtD
Esmolol—Feeling abnormal—Docetaxel—melanoma	0.00135	0.00158	CcSEcCtD
Esmolol—Body temperature increased—Docetaxel—melanoma	0.00129	0.00151	CcSEcCtD
Esmolol—Asthenia—Docetaxel—melanoma	0.00117	0.00138	CcSEcCtD
Esmolol—Pruritus—Docetaxel—melanoma	0.00116	0.00136	CcSEcCtD
Esmolol—Propafenone—ABCB1—melanoma	0.00112	0.0496	CrCbGaD
Esmolol—Dizziness—Docetaxel—melanoma	0.00108	0.00127	CcSEcCtD
Esmolol—Vomiting—Docetaxel—melanoma	0.00104	0.00122	CcSEcCtD
Esmolol—Ibuprofen—PTGS2—melanoma	0.00103	0.0454	CrCbGaD
Esmolol—Headache—Docetaxel—melanoma	0.00102	0.0012	CcSEcCtD
Esmolol—Nausea—Docetaxel—melanoma	0.000971	0.00114	CcSEcCtD
Esmolol—Ibuprofen—ALB—melanoma	0.000916	0.0404	CrCbGaD
Esmolol—Ibuprofen—ABCB1—melanoma	0.000874	0.0386	CrCbGaD
Esmolol—Propranolol—ABCB1—melanoma	0.00077	0.034	CrCbGaD
Esmolol—ADRB2—Signaling Pathways—GRM3—melanoma	0.000154	0.00123	CbGpPWpGaD
Esmolol—ADRB1—GPCR downstream signaling—GNAQ—melanoma	0.000152	0.00122	CbGpPWpGaD
Esmolol—ADRB2—GPCR downstream signaling—CXCR4—melanoma	0.00015	0.00121	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—KISS1—melanoma	0.000149	0.00119	CbGpPWpGaD
Esmolol—ADRB2—GPCR downstream signaling—GNAQ—melanoma	0.000149	0.00119	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—GAB2—melanoma	0.000149	0.00119	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—GNA11—melanoma	0.000149	0.00119	CbGpPWpGaD
Esmolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	0.000148	0.00119	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—KISS1—melanoma	0.000146	0.00117	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—GAB2—melanoma	0.000145	0.00116	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—GNA11—melanoma	0.000145	0.00116	CbGpPWpGaD
Esmolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	0.000145	0.00116	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—SKI—melanoma	0.000144	0.00116	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—CXCR1—melanoma	0.000144	0.00116	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—MC1R—melanoma	0.000142	0.00114	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—SKI—melanoma	0.000141	0.00113	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—CXCR1—melanoma	0.000141	0.00113	CbGpPWpGaD
Esmolol—ADRB1—GPCR downstream signaling—AKT3—melanoma	0.00014	0.00112	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—CXCR4—melanoma	0.00014	0.00112	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—MC1R—melanoma	0.000139	0.00111	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—GNAQ—melanoma	0.000138	0.00111	CbGpPWpGaD
Esmolol—ADRB2—GPCR downstream signaling—AKT3—melanoma	0.000137	0.0011	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—CXCR4—melanoma	0.000137	0.00109	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—CCR7—melanoma	0.000136	0.00109	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—GRM1—melanoma	0.000136	0.00109	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—GNAQ—melanoma	0.000135	0.00108	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—CCR7—melanoma	0.000133	0.00107	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—GRM1—melanoma	0.000133	0.00107	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—SUFU—melanoma	0.000133	0.00106	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—SUFU—melanoma	0.00013	0.00104	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—AKT3—melanoma	0.000127	0.00102	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—AKT3—melanoma	0.000125	0.000999	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—BCL2L11—melanoma	0.000124	0.000993	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—RHOB—melanoma	0.000124	0.000993	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—BCL2L11—melanoma	0.000121	0.000971	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—RHOB—melanoma	0.000121	0.000971	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—HDAC6—melanoma	0.000119	0.000954	CbGpPWpGaD
Esmolol—ADRB1—GPCR downstream signaling—EDN1—melanoma	0.000118	0.000945	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—HDAC6—melanoma	0.000116	0.000933	CbGpPWpGaD
Esmolol—ADRB2—GPCR downstream signaling—EDN1—melanoma	0.000115	0.000924	CbGpPWpGaD
Esmolol—ADRB1—GPCR downstream signaling—CSF2—melanoma	0.000115	0.000924	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—CXCR2—melanoma	0.000113	0.000904	CbGpPWpGaD
Esmolol—ADRB1—GPCR ligand binding—CXCL8—melanoma	0.000113	0.000904	CbGpPWpGaD
Esmolol—ADRB2—GPCR downstream signaling—CSF2—melanoma	0.000113	0.000904	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—RAC2—melanoma	0.000111	0.00089	CbGpPWpGaD
Esmolol—ADRB1—GPCR downstream signaling—PRKCA—melanoma	0.00011	0.000886	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—CXCR2—melanoma	0.00011	0.000885	CbGpPWpGaD
Esmolol—ADRB2—GPCR ligand binding—CXCL8—melanoma	0.00011	0.000884	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—WNT5A—melanoma	0.000109	0.000876	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—VEGFC—melanoma	0.000109	0.000876	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—RAC2—melanoma	0.000109	0.00087	CbGpPWpGaD
Esmolol—ADRB2—GPCR downstream signaling—PRKCA—melanoma	0.000108	0.000866	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—EDN1—melanoma	0.000107	0.000858	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—WNT5A—melanoma	0.000107	0.000857	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—VEGFC—melanoma	0.000107	0.000857	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—EDN1—melanoma	0.000105	0.000839	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—CSF2—melanoma	0.000105	0.000839	CbGpPWpGaD
Esmolol—ADRB1—GPCR downstream signaling—RAC1—melanoma	0.000102	0.000821	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—CSF2—melanoma	0.000102	0.00082	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—PRKCA—melanoma	0.0001	0.000804	CbGpPWpGaD
Esmolol—ADRB2—GPCR downstream signaling—RAC1—melanoma	0.0001	0.000803	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—PRKCA—melanoma	9.81e-05	0.000787	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—MAP2K2—melanoma	9.81e-05	0.000786	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—MAP2K2—melanoma	9.59e-05	0.000769	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—F2R—melanoma	9.59e-05	0.000769	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—F2R—melanoma	9.38e-05	0.000752	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—RAC1—melanoma	9.3e-05	0.000746	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—EDNRB—melanoma	9.29e-05	0.000745	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—RAC1—melanoma	9.1e-05	0.000729	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—EDNRB—melanoma	9.09e-05	0.000728	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—PTK2B—melanoma	9.02e-05	0.000723	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—PTK2B—melanoma	8.82e-05	0.000707	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—GAB2—melanoma	8.77e-05	0.000703	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—GNA11—melanoma	8.77e-05	0.000703	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—FLT1—melanoma	8.74e-05	0.0007	CbGpPWpGaD
Esmolol—ADRB1—GPCR downstream signaling—PIK3CG—melanoma	8.65e-05	0.000694	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—GAB2—melanoma	8.58e-05	0.000688	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—GNA11—melanoma	8.58e-05	0.000688	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—FLT1—melanoma	8.54e-05	0.000685	CbGpPWpGaD
Esmolol—ADRB2—GPCR downstream signaling—PIK3CG—melanoma	8.47e-05	0.000678	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—HDAC2—melanoma	8.25e-05	0.000661	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—FOXO4—melanoma	8.25e-05	0.000661	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—CXCR4—melanoma	8.25e-05	0.000661	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—GNAQ—melanoma	8.16e-05	0.000654	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—HDAC2—melanoma	8.07e-05	0.000647	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—CXCR4—melanoma	8.07e-05	0.000647	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—FOXO4—melanoma	8.07e-05	0.000647	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—GNAQ—melanoma	7.98e-05	0.00064	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—PIK3CG—melanoma	7.86e-05	0.00063	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—PIK3CG—melanoma	7.69e-05	0.000616	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—SYK—melanoma	7.67e-05	0.000615	CbGpPWpGaD
Esmolol—ADRB1—GPCR downstream signaling—PIK3CD—melanoma	7.61e-05	0.00061	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—AKT3—melanoma	7.53e-05	0.000603	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—NGFR—melanoma	7.53e-05	0.000603	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—ITGAV—melanoma	7.53e-05	0.000603	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—SYK—melanoma	7.5e-05	0.000601	CbGpPWpGaD
Esmolol—ADRB2—GPCR downstream signaling—PIK3CD—melanoma	7.44e-05	0.000596	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—NGFR—melanoma	7.36e-05	0.00059	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—ITGAV—melanoma	7.36e-05	0.00059	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—AKT3—melanoma	7.36e-05	0.00059	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—SOCS1—melanoma	6.97e-05	0.000559	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—MAP2K1—melanoma	6.95e-05	0.000557	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—S100B—melanoma	6.95e-05	0.000557	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—PIK3CD—melanoma	6.91e-05	0.000554	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—SOCS1—melanoma	6.82e-05	0.000547	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—MAP2K1—melanoma	6.8e-05	0.000545	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—S100B—melanoma	6.8e-05	0.000545	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—PIK3CD—melanoma	6.76e-05	0.000542	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—ERBB4—melanoma	6.65e-05	0.000533	CbGpPWpGaD
Esmolol—ADRB1—GPCR downstream signaling—PIK3CB—melanoma	6.63e-05	0.000531	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—CDKN2B—melanoma	6.59e-05	0.000528	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—ERBB4—melanoma	6.5e-05	0.000521	CbGpPWpGaD
Esmolol—ADRB2—GPCR downstream signaling—PIK3CB—melanoma	6.49e-05	0.00052	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—CDKN2B—melanoma	6.45e-05	0.000517	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—CD86—melanoma	6.38e-05	0.000511	CbGpPWpGaD
Esmolol—ADRB1—GPCR downstream signaling—CXCL8—melanoma	6.37e-05	0.000511	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—EDN1—melanoma	6.32e-05	0.000507	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—CD86—melanoma	6.24e-05	0.0005	CbGpPWpGaD
Esmolol—ADRB2—GPCR downstream signaling—CXCL8—melanoma	6.23e-05	0.0005	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—EDN1—melanoma	6.19e-05	0.000496	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—CSF2—melanoma	6.18e-05	0.000495	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—FGF1—melanoma	6.18e-05	0.000495	CbGpPWpGaD
Esmolol—ADRB1—GPCR downstream signaling—IL2—melanoma	6.09e-05	0.000488	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—E2F1—melanoma	6.05e-05	0.000485	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—FGF1—melanoma	6.05e-05	0.000485	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—CSF2—melanoma	6.05e-05	0.000485	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—PIK3CB—melanoma	6.02e-05	0.000483	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—PDGFRA—melanoma	5.99e-05	0.00048	CbGpPWpGaD
Esmolol—ADRB2—GPCR downstream signaling—IL2—melanoma	5.96e-05	0.000477	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—ITGB3—melanoma	5.93e-05	0.000475	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—PRKCA—melanoma	5.93e-05	0.000475	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—E2F1—melanoma	5.92e-05	0.000474	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—PIK3CB—melanoma	5.89e-05	0.000472	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—PDGFRA—melanoma	5.86e-05	0.000469	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—SPP1—melanoma	5.81e-05	0.000466	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—ITGB3—melanoma	5.8e-05	0.000465	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—PRKCA—melanoma	5.8e-05	0.000465	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—MAP2K2—melanoma	5.79e-05	0.000464	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—CXCL8—melanoma	5.79e-05	0.000464	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—SPP1—melanoma	5.69e-05	0.000456	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—MAP2K2—melanoma	5.67e-05	0.000454	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—CXCL8—melanoma	5.66e-05	0.000454	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—IL2—melanoma	5.53e-05	0.000443	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—TERT—melanoma	5.51e-05	0.000442	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—RAC1—melanoma	5.49e-05	0.00044	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—IL2—melanoma	5.41e-05	0.000434	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—TERT—melanoma	5.39e-05	0.000432	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—RAC1—melanoma	5.37e-05	0.000431	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—HIF1A—melanoma	5.27e-05	0.000422	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—HIF1A—melanoma	5.15e-05	0.000413	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—KDR—melanoma	5.04e-05	0.000404	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—KDR—melanoma	4.93e-05	0.000395	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—FN1—melanoma	4.85e-05	0.000389	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—NOTCH1—melanoma	4.75e-05	0.00038	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—FN1—melanoma	4.75e-05	0.00038	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—CD80—melanoma	4.65e-05	0.000373	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—NOTCH1—melanoma	4.64e-05	0.000372	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—KIT—melanoma	4.64e-05	0.000372	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—PIK3CG—melanoma	4.64e-05	0.000372	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—APC—melanoma	4.64e-05	0.000372	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—NRAS—melanoma	4.64e-05	0.000372	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—EGF—melanoma	4.59e-05	0.000368	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—CD80—melanoma	4.55e-05	0.000365	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—PIK3CG—melanoma	4.54e-05	0.000364	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—KIT—melanoma	4.54e-05	0.000364	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—APC—melanoma	4.54e-05	0.000364	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—NRAS—melanoma	4.54e-05	0.000364	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—EGF—melanoma	4.49e-05	0.00036	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—MAPK3—melanoma	4.45e-05	0.000356	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—BRAF—melanoma	4.36e-05	0.00035	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—MAPK3—melanoma	4.35e-05	0.000349	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—BRAF—melanoma	4.27e-05	0.000342	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—IGF1—melanoma	4.25e-05	0.000341	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—MAPK1—melanoma	4.23e-05	0.000339	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—EGFR—melanoma	4.23e-05	0.000339	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—IGF1—melanoma	4.16e-05	0.000333	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—MAPK1—melanoma	4.14e-05	0.000332	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—EGFR—melanoma	4.14e-05	0.000332	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—MAP2K1—melanoma	4.11e-05	0.000329	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—PIK3CD—melanoma	4.08e-05	0.000327	CbGpPWpGaD
Esmolol—ADRB1—GPCR downstream signaling—PIK3CA—melanoma	4.04e-05	0.000324	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—MAP2K1—melanoma	4.02e-05	0.000322	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—KRAS—melanoma	4e-05	0.00032	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—PIK3CD—melanoma	3.99e-05	0.00032	CbGpPWpGaD
Esmolol—ADRB2—GPCR downstream signaling—PIK3CA—melanoma	3.95e-05	0.000317	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—KRAS—melanoma	3.91e-05	0.000313	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—FGF2—melanoma	3.91e-05	0.000313	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—FGF2—melanoma	3.82e-05	0.000306	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—PIK3CA—melanoma	3.67e-05	0.000294	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—MDM2—melanoma	3.66e-05	0.000293	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—ERBB2—melanoma	3.6e-05	0.000289	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—PIK3CA—melanoma	3.59e-05	0.000288	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—MDM2—melanoma	3.58e-05	0.000287	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—PIK3CB—melanoma	3.56e-05	0.000285	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—ERBB2—melanoma	3.53e-05	0.000283	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—PIK3CB—melanoma	3.48e-05	0.000279	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—CXCL8—melanoma	3.42e-05	0.000274	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—HRAS—melanoma	3.4e-05	0.000272	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—CXCL8—melanoma	3.34e-05	0.000268	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—CDKN1B—melanoma	3.34e-05	0.000268	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—HRAS—melanoma	3.32e-05	0.000266	CbGpPWpGaD
Esmolol—ADRB1—GPCR downstream signaling—AKT1—melanoma	3.3e-05	0.000265	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—CASP3—melanoma	3.27e-05	0.000262	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—IL2—melanoma	3.27e-05	0.000262	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—CDKN1B—melanoma	3.27e-05	0.000262	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—IL6—melanoma	3.25e-05	0.000261	CbGpPWpGaD
Esmolol—ADRB2—GPCR downstream signaling—AKT1—melanoma	3.23e-05	0.000259	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—CASP3—melanoma	3.2e-05	0.000257	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—IL2—melanoma	3.2e-05	0.000256	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—CCND1—melanoma	3.18e-05	0.000255	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—IL6—melanoma	3.18e-05	0.000255	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—CTNNB1—melanoma	3.15e-05	0.000253	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—CCND1—melanoma	3.12e-05	0.00025	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—MMP9—melanoma	3.09e-05	0.000248	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—CTNNB1—melanoma	3.08e-05	0.000247	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—CDKN1A—melanoma	3.08e-05	0.000247	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—PTEN—melanoma	3.07e-05	0.000246	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—NFKB1—melanoma	3.06e-05	0.000245	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—MMP9—melanoma	3.02e-05	0.000242	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—CDKN1A—melanoma	3.01e-05	0.000242	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—PTEN—melanoma	3.01e-05	0.000241	CbGpPWpGaD
Esmolol—ADRB1—Signaling by GPCR—AKT1—melanoma	3e-05	0.00024	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—NFKB1—melanoma	2.99e-05	0.00024	CbGpPWpGaD
Esmolol—ADRB2—Signaling by GPCR—AKT1—melanoma	2.93e-05	0.000235	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—VEGFA—melanoma	2.78e-05	0.000223	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—STAT3—melanoma	2.75e-05	0.00022	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—NRAS—melanoma	2.74e-05	0.00022	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—VEGFA—melanoma	2.72e-05	0.000218	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—STAT3—melanoma	2.69e-05	0.000216	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—NRAS—melanoma	2.68e-05	0.000215	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—MAPK3—melanoma	2.63e-05	0.000211	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—MAPK3—melanoma	2.57e-05	0.000206	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—MYC—melanoma	2.55e-05	0.000205	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—MAPK1—melanoma	2.5e-05	0.0002	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—MYC—melanoma	2.5e-05	0.0002	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—EGFR—melanoma	2.5e-05	0.0002	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—MAPK1—melanoma	2.44e-05	0.000196	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—EGFR—melanoma	2.44e-05	0.000196	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—KRAS—melanoma	2.36e-05	0.000189	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—KRAS—melanoma	2.31e-05	0.000185	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—PIK3CA—melanoma	2.17e-05	0.000174	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—PIK3CA—melanoma	2.12e-05	0.00017	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—TP53—melanoma	2.1e-05	0.000168	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—TP53—melanoma	2.05e-05	0.000164	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—HRAS—melanoma	2.01e-05	0.000161	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—HRAS—melanoma	1.96e-05	0.000157	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—IL6—melanoma	1.92e-05	0.000154	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—IL6—melanoma	1.88e-05	0.000151	CbGpPWpGaD
Esmolol—ADRB1—Signaling Pathways—AKT1—melanoma	1.77e-05	0.000142	CbGpPWpGaD
Esmolol—ADRB2—Signaling Pathways—AKT1—melanoma	1.73e-05	0.000139	CbGpPWpGaD
